AbbVie Inc ABBV revealed top-line arise from the COMMAND Stage 3 upkeep research, revealing risankizumab (Skyrizi) accomplished the main endpoint of professional remission at week 52, in addition to crucial second endpoints in reasonably to seriously energetic ulcerative colitis.
A considerably greater percentage of individuals that obtained risankizumab 180 mg or 360 mg accomplished professional remission at week 52: 40% and also 38%, specifically, contrasted to 25% in the induction-only control team.
51% of individuals treated with risankizumab 180 mg and also 48% treated with risankizumab 360 mg accomplished endoscopic enhancement at week 52 vs. 32% of individuals in the induction-only control team.
Furthermore, substantially much more individuals treated with risankizumab 180 mg and also 360 mg accomplished histologic endoscopic mucosal enhancement at week 52 contrasted to those treated with induction just: 43% and also 42%, specifically, vs. 23%.
A considerably greater percentage of individuals that obtained risankizumab 180 mg or 360 mg accomplished steroid-free professional remission contrasted to the induction-only control team at week 52 (40% and also 37%, specifically, vs. 25%).
Cost Activity: ABBV shares are down 0.32% at $135.80 on the last check Thursday.
